**EXPLANATORY STATEMENT**

*Therapeutic Goods Act 1989*

*Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2020*

The *Therapeutic Goods Act 1989* (“the Act”) provides for the establishment and maintenance of a national system of controls for the quality, safety, efficacy and timely availability of therapeutic goods that are used in, or exported from, Australia. The Act is administered by the Therapeutic Goods Administration (“the TGA”) within the Australian Government Department of Health.

Section 26BB of the Act relevantly provides that the Minister of Health may, by legislative instrument, make a determination specifying ingredients and, for some or all of those ingredients, requirements in relation to those ingredients being contained in a medicine. Under subsections 26BB(2), (2A) and (3) of the Act, such requirements may relate to particular ingredients not being contained in particular medicines or being contained in particular medicines only in specified circumstances or to permitted concentrations or total amounts of an ingredient in a medicine.

Legislative instruments made under section 26BB of the Act are designed to specify those ingredients that may be contained in a medicine that is listed in the Australian Register of Therapeutic Goods (“the Register”) under section 26A or 26AE of the Act, and to specify requirements in relation to the inclusion of those ingredients in such medicines.

The *Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2020* (“the Determination”) repeals and replaces the *Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2020* (“the former Determination”), and specifies those ingredients that may be contained in a medicine that is listed in the Register and requirements in relation to the inclusion of those ingredients in such medicines.

**Background**

Medicines that are listed in the Register under section 26A of the Act are considered to be low risk and are not individually evaluated before those medicines are listed. Medicines that are listed in the Register under section 26AE of the Act are also considered to be low risk, but are evaluated in relation to whether the efficacy of the medicine for the purposes for which it is to be used has been satisfactorily established (these purposes are specific efficacy claims for which the sponsor of the medicine holds supporting evidence). When listed under section 26AE, these listed medicines are commonly referred to as ‘assessed listed medicines’.

As the safety and quality of medicines listed under sections 26A and 26AE are not evaluated by the TGA before being given marketing approval, the Act contains mechanisms to help ensure that those medicines are of appropriate quality and able to be used safely by consumers. In particular, medicines listed under section 26A and 26AE may only contain ingredients from an approved list of ingredients that have been evaluated in relation to their quality and safety and suitability for use in such medicines. Sponsors of such medicines may also only use indications (statements of therapeutic use) from a list of pre-approved low level indications to ensure that these products do not overstate their therapeutic benefits.

Under paragraphs 26A(2)(ca) and (cb) of the Act, persons applying to list a medicine in the Register under section 26A of the Act must certify that the medicine does not contain an ingredient that is not specified in a determination under paragraph 26BB(1)(a) of the Act; and does not contravene a requirement in relation to such an ingredient that is specified in such a determination. Paragraphs 26AB(2)(d) and (e) contain equivalent certification requirements for applicants seeking marketing approval in relation to assessed listed medicines. A listed (or assessed listed) medicine may be cancelled from the Register if it appears to the Secretary that such a certification is incorrect.

Separately, items 3, 4A, 5, 7 and 8 of Schedule 4 to the *Therapeutic Goods Regulations 1990* (“the Regulations”), which identifies those therapeutic goods that are eligible for listing in the Register, require that, in order for the goods mentioned in each of those items to be eligible for listing, the goods must only contain ingredients that are specified in a determination under paragraph 26BB(1)(a) of the Act and must not contravene a requirement in such a determination.

As such, determinations under section 26BB are designed to provide a comprehensive list of ingredients which have been assessed or otherwise considered to be safe for use in listed medicines (including assessed listed medicines), and associated requirements to be followed when using particular ingredients in such products. These requirements may relate to a range of matters including, for example, how an ingredient may be used in a medicine or the inclusion of relevant safety information on product labels.

The requirements imposed under the Determination are principally designed to ensure or support the quality and safety of listed medicines that contain permitted ingredients. The requirements may relate to, for example:

* how a permitted ingredient is to be used in the medicine, that is, as an active, homoeopathic or excipient ingredient;
* the intended method of ingestion or application of the medicine, for example, oral or topical use;
* the source of the ingredient, or procedures to be followed in its manufacture;
* appropriate limits on the volume or concentration of an ingredient; and
* the inclusion of relevant safety information on product labels, for example, allergen advice or advice about the use of medicine containing the ingredient for susceptible members of the population such as children and pregnant women.

The Determination incorporates a number of changes in comparison to the former Determination, including in particular:

* the introduction of 27 new ingredients for use in listed and assessed listed medicines. These ingredients reflect particular proprietary formulations that are and have been included in listed medicines in Australia for some time but were inadvertently omitted from the first (and subsequent) determinations under section 26BB of the Act. These ingredient were reviewed by the TGA and determined to be appropriate for the existing use in listed medicines;
* the amendment of requirements related to the ingredient arbutin (a component of 11 herbal ingredients) to align with updated specifications in the *Poisons Standard October 2020* for arbutin derivatives including beta-arbutin;
* minor amendments to 31 ingredients to reflect the expiry of transition periods for requirements relating to those ingredients;
* updating the names of 9 herbal ingredients to align them with current taxonomy;
* the removal of requirements for the following three ingredients to reflect the expiry of periods of exclusive uses for sponsors:
	+ *Khaya senegalensis*;
	+ sodium polyacrylate starch; and
	+ capryloyl glycerine sebacic acid copolymer; and
* the removal of the following three ingredients to reflect safety and consistency concerns:
	+ *Fallopia multiflora*,due to the risk of severe liver damage associated with its use;
	+ methyldibromo glutaronitrile, to reflect that this ingredient is included in Schedule 10 to the Poisons Standard and that the eligibility criteria for listing in Schedule 4 to the Regulations require that to be listable a medicine must not contain a substance that is included in a schedule to the Poisons Standard; and
	+ dimethyl sulfate, to reflect that this ingredient is included in Schedule 7 to the Poisons Standard and that the eligibility criteria for listing in Schedule 4 to the Regulations require that to be listable a medicine must not contain a substance that is included in a schedule to the Poisons Standard.

**Consultation**

Public consultation was undertaken in accordance with Subdivision 3D.2 of Division 6 of the Regulations on the proposed inclusion of arbutin derivatives in the *Poisons Standard October 2020*. The TGA engaged directly with the applicant for the inclusion of arbutin derivatives in the *Poisons Standard October 2020* in connection with aligning the Determination with that inclusion.

The TGA published safety advice on the ingredient *Fallopia multiflora* on the TGA’s website in April 2019, alerting consumers and health professionals of the potential for liver damage associated with *Fallopia multiflora* and that a review of the issue was ongoing. The TGA also sought advice on this issue of the safety of this ingredient from the [Advisory Committee on Complementary Medicines (“the ACCM”)](https://www.tga.gov.au/committee/advisory-committee-complementary-medicines-accm) at its [24th meeting](https://www.tga.gov.au/committee-meeting-info/accm-meeting-statement-meeting-24-19-march-2020) on 19 March 2020.

The advice from the ACCM included that, in light of those safety concerns, the currently available forms of *Fallopia multiflora* are not suitable for use in listed or assessed listed medicines, and the ACCM recommended healthcare professionals be notified about the risks of such products for consumers. Following that advice, the TGA alerted the Chinese Medicine Board of Australia on 18 November 2020, who advised that they would communicate the risk to their registered practitioners and other key stakeholders.

On 22 July 2020 the TGA wrote directly to all sponsors of listed medicines containing *Fallopia multiflora* about the risk and encouraged them to provide information to support the safety of their medicines. The responses received did not establish that the safety profile of listed medicines containing this ingredient was appropriate, and the medicines were cancelled from the Register and recalled from the Australian market, in light of the safety concerns.

On 4 August 2020 the TGA contacted Complementary Medicines Australia (CMA), the Chinese Medicines Industry Council (CMIC) and Consumer Healthcare Products Australia in relation to the issue. CMA and CMIC suggested the possible inclusion of requirements relating to the use of the ingredient of *Fallopia multiflora* in listed or listed assessed medicines to mitigate the risks associated with the use of the ingredient. Those suggestions were carefully considered, but there did not appear to be sufficient evidence to support a conclusion that the serious risk of liver damage associated with the ingredient could be effectively managed in the context of the listed and assessed listed medicines framework.

The changes in the Determination in comparison with the former Determination to reflect the expiry of transition periods for ingredient requirements were the subject of discussions between the TGA, CMA and medicine sponsors.

The other changes in the Determination in comparison with the former Determination were minor and machinery in nature, e.g. to correct errors or remove irrelevant requirements, and were not the subject of consultation.

The Office of Best Practice Regulation (“OBPR”) has also previously advised that a regulatory impact statement is not required for updates to determinations made under section 26BB of the Act that are minor or machinery in nature, including the introduction of new permitted ingredients, corrections of errors, clarifications of requirements and ingredient names, changes to reflect scheduling decisions in the Poisons Standard or the outcomes of TGA safety evaluations where the regulatory impacts are minor or machinery in nature (OBPR references 14416, 20999 and 21645).

**Incorporation by reference**

The Determination references each of the British Pharmacopoeia, European Pharmacopoeia and United States Pharmacopeia-National Formulary, and the note in section 4 of the Determination makes it clear that each of these pharmacopoeia are those as defined in subsection 3(1) of the Act.

The definitions of the pharmacopoeia in subsection 3(1) of the Act refer to the publications of each as in effect immediately before the commencement of the relevant definition in the Act, and to any subsequent amendments or editions. The intention in this Determination is therefore to adopt the defined meaning of the pharmacopoeia as set out in subsection 3(1) of the Act (an approach permitted by subsection 26BB(8) of the Act). That pharmacopoeia may be accessed from [www.pharmacopoeia.com/](http://www.pharmacopoeia.com/), [www.edqm.eu/en/european-pharmacopoeia-ph-eur-9th-edition](http://www.edqm.eu/en/european-pharmacopoeia-ph-eur-9th-edition) and [www.uspnf.com/](http://www.uspnf.com/).

The Determination also adopts the Food Chemicals Codex (“the FCC”) published by the United States Pharmacopeial Convention (available at [www.online.foodchemicalscodex.org](http://www.online.foodchemicalscodex.org)). The intended manner of adoption of the FCC is also as it is in force or existing from time to time, as permitted by subsection 26BB(8) of the Act. The Determination adopts each of the *Animal Products Act 1999* and the *Animal Welfare Act 1999* of New Zealand on the same basis. These Acts are available for free from [www.legislation.govt.nz/](http://www.legislation.govt.nz/).

The Determination also includes a reference to a World Health Organization publication ‘*Expert consultation on oral rehydration salts formulation*’, dated 18 July 2001. This document is available for free from [www.rehydrate.org/ors/expert-consultation.html](http://www.rehydrate.org/ors/expert-consultation.html).

While unfortunately the pharmacopoeia and the FCC are not available for free, it is anticipated that the persons most affected by their adoption in this Determination (sponsors of medicines included in the Register and other interested persons in the medicines industry using the Determination), would be in possession of these documents in order to manufacture medicines or ingredients. As important international benchmarks for the safety and quality of therapeutic goods, it would be infeasible from a regulatory perspective (particularly in relation to the safety of listed medicines that are not, for the most part, evaluated before being given marketing approval) to not adopt such benchmarks on the basis that the publications are not available for free.

However, by prior written arrangement with the TGA, members of the public may request to view the pharmacopoeia and the FCC without charge at the TGA office in Symonston, ACT.

It should also be noted, in relation to the pharmacopoeia, that the National Library’s Trove online system ([www.trove.nla.gov.au/](http://www.trove.nla.gov.au/)) allows users to identify libraries in Australia that are open to the public where editions (in most cases, earlier editions) of the pharmacopoeia may be viewed (for example, the University of Tasmania or the University of Western Australia in relation to the British Pharmacopoeia). Members of the public may also approach any library that participates in inter-library loans with those university libraries to request an inter-library loan, or to obtain a photocopy of a particular part or monograph for personal study or research (but not for commercial purposes), at a usual cost of $16.50 per request (enquiries should be made with local libraries, State libraries and the National Library).

For example, Trove indicates that free access to the 2004 version of the European Pharmacopoeia is available through Open University ([www.openlibrary.org/books/OL22071008M/European\_pharmacopoeia](http://www.openlibrary.org/books/OL22071008M/European_pharmacopoeia)), and that access to the 1996 edition of the FCC is available at the University of Melbourne Library and the Hawksbury Campus Library of the Western Sydney University, which are both open to the public.

Details of the Determination are set out in **Attachment A**.

The Determination is compatible with the human rights and freedoms recognised or declared under section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*. A full statement of compatibility is set out in **Attachment B**.

This Determination is a disallowable legislative instrument for the purposes of the *Legislation Act 2003*, and commences the day after registration.

**Attachment A**

**Details of the *Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2020***

**Section 1 Name**

This section provides that the name of the instrument is the *Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2020* (“the Determination”).

**Section 2 Commencement**

This section provides that the Determination commences the day after registration.

**Section 3 Authority**

This section provides that the legislative authority for making the Determination is subsection 26BB(1) of the *Therapeutic Goods Act 1989* (“the Act”).

**Section 4 Interpretation**

Subsection 4(1) provides definitions for a number of terms used in the Determination. These include ‘code tables’, ‘excipient’, ‘homoeopathic preparation ingredient’ and ‘TGA eBusiness Services’.

The note to this section also makes it clear that a number of expressions used in the Determination have the same meaning as in the Act, for example ‘British Pharmacopoeia’, ‘European Pharmacopoeia’ and ‘United States Pharmacopeia-National Formulary’.

Subsection 4(2) provides that the terms set out in closed brackets in column 4 of the table in Schedule 1 to the Determination that are associated with warning statements in relation to particular ingredients, are terms from the code tables under the heading ‘Product Warning’, and are not required to be included on the label of the medicine.

**Section 5 Permissible ingredients**

This section provides that the ingredients specified in column 2 of the table in Schedule 1 to the Determination are specified for the purposes of paragraph 26BB(1)(a) of the Act.

**Section 6 Requirements in relation to permissible ingredients being contained in medicine**

This section provides that for an ingredient mentioned in column 2 of an item in the table in Schedule 1 to the Determination, the requirements in paragraphs 6(a) to (c) are specified for the purposes of paragraph 26BB(1)(b) of the Act. These include, for example, that the ingredient must only be used in a medicine for a purpose specified in relation to the ingredient in column 3 of that item.

**Section 7 Repeals**

This section provides that each instrument that is specified in Schedule 2 to the Determination is repealed as set out in the applicable items in that Schedule.

**Schedule 1 – Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine**

This Schedule specifies ingredients and related requirements for the purposes of sections 5 and 6 of the Determination.

**Schedule 2 – Repeals**

This Schedule repeals the *Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2020.*

**Attachment B**

**Statement of Compatibility with Human Rights**

*Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.*

***Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2020***

This disallowable legislative instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

**Overview of the Legislative Instrument**

The *Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2020* (“the instrument”) is made by a delegate of the Minister under subsection 26BB(1) of the *Therapeutic Goods Act 1989* (“the Act”)*.*

The purpose of the instrument is to specify those ingredients that may be contained in a medicine that is listed in the Australian Register of Therapeutic Goods (“the Register”) under section 26A or 26AE of the Act, and requirements in relation to the inclusion of those ingredients in such medicines. The instrument repeals and replaces the existing *Therapeutic Goods (Permissible Ingredients) Determination (No. 3)* 2020 (“the former instrument”).

Medicines that are listed in the Register under section 26A of the Act are considered to be low risk and are not individually evaluated before they are listed. Medicines that are listed in the Register under section 26AE of the Act are also considered to be low risk, but are evaluated in relation to whether the efficacy of the medicine for the purposes for which it is to be used has been satisfactorily established (these purposes are specific efficacy claims for which the sponsor of the medicine holds supporting evidence). When listed under section 26AE, these listed medicines are commonly referred to as ‘assessed listed medicines’.

As the safety and quality of medicines listed under section 26A and 26AE are not evaluated by the Therapeutic Goods Administration (“the TGA”) before being given marketing approval, the Act contains mechanisms to help ensure that listed medicines are of appropriate quality and able to be used safely by consumers. In particular, listed medicines may only contain ingredients from an approved list of ingredients that have been evaluated in relation to their quality and safety and suitability for use in such medicines.

Under paragraphs 26A(2)(ca) and (cb) of the Act, persons applying to list a medicine in the Register under section 26A of the Act must certify that their medicine does not contain an ingredient that is not specified in a determination under paragraph 26BB(1)(a) of the Act, and does not contravene a requirement in relation to such an ingredient that is specified in such a determination. Paragraphs 26AB(2)(d) and (e) set out equivalent certification requirements for applicants seeking marketing approval for an assessed listed medicine. A listed (or assessed listed) medicine may be cancelled from the Register if it appears to the Secretary that such a certification is incorrect.

Compliance with the instrument is also an important part of the criteria for eligibility for listing of medicines in the Register set out in Schedule 4 to the *Therapeutic Goods Regulations 1990*. Medicines that are not eligible for listing because those medicines do not comply with these criteria (including compliance with the instrument) would be required to be registered, rather than listed, in the Register (a considerably more lengthy and costly exercise).

The instrument is designed to provide a comprehensive list of ingredients which have been assessed or otherwise considered to be safe for use in listed (and assessed listed) medicines, and associated requirements to be followed when using particular ingredients in such products, to support the overall safety of these products for consumers.

The requirements imposed under the instrument principally relate to ensuring the quality and safety of the ingredient when used. Requirements may relate, for example, to:

* how the ingredient is to be used in the medicine, that is, as an active, homoeopathic or excipient ingredient;
* the intended method of ingestion or application of the medicine, for example, oral or topical use;
* the source of the ingredient, or procedures to be followed in its manufacture;
* appropriate limits on the volume or concentration of an ingredient; and
* the inclusion of relevant safety information on product labels, for example, allergen advice or advice about the use of medicine containing the ingredient for susceptible members of the population such as children and pregnant women.

The instrument repeals and replaces the former instrument, and incorporates a number of changes in comparison to the former instrument, including in particular:

* the introduction of 27 new ingredients for use in listed and assessed listed medicines. These ingredients reflect particular proprietary formulations that are and have been included in listed medicines in Australia for some time but were inadvertently omitted from the first (and subsequent) determinations under section 26BB of the Act. These ingredient were reviewed by the TGA and determined to be appropriate for the existing use in listed medicines;
* the amendment of requirements related to the ingredient arbutin (a component of 11 herbal ingredients) to align with updated specifications in the *Poisons Standard October 2020* for arbutin derivatives including beta-arbutin;
* minor amendments to 31 ingredients to reflect the expiry of transition periods for requirements relating to those ingredients;
* updating the names of 9 herbal ingredients to align them with current taxonomy;
* the removal of requirements for the following three ingredients to reflect the expiry of periods of exclusive uses for sponsors:
	+ *Khaya senegalensis*;
	+ sodium polyacrylate starch; and
	+ capryloyl glycerine sebacic acid copolymer; and
* the removal of the following three ingredients to reflect safety and consistency concerns:
	+ *Fallopia multiflora*,due to the risk of severe liver damage associated with its use;
	+ methyldibromo glutaronitrile, to reflect that this ingredient is included in Schedule 10 to the Poisons Standard and that the eligibility criteria for listing in Schedule 4 to the Regulations require that to be listable a medicine must not contain a substance that is included in a schedule to the Poisons Standard; and
	+ dimethyl sulfate, to reflect that this ingredient is included in Schedule 7 to the Poisons Standard and that the eligibility criteria for listing in Schedule 4 to the Regulations require that to be listable a medicine must not contain a substance that is included in a schedule to the Poisons Standard.

**Human rights implications**

The instrument engages the right to health in Article 12 of the International Covenant on Economic, Social and Cultural Rights (“the ICESCR”). Article 12 of the ICESCR promotes the right of all individuals to enjoy the highest attainable standard of physical and mental health, and includes an obligation to take reasonable measures within available resources to progressively secure broader enjoyment of the right. In *General Comment No. 14: The Right to the Highest Attainable Standard of Health (Art. 12)* (2000), the United Nations Committee on Economic, Social and Cultural Rights states that health is a ‘fundamental human right indispensable for the exercise of other human rights’, and that the right to health is not to be understood as the right to be healthy, but includes the right to a system of health protection which provides equal opportunity for people to enjoy the highest attainable level of health.

The instrument takes positive steps to promote the right to health by ensuring the safety and quality of therapeutic goods that are listed medicines. By prescribing those ingredients that are considered to be safe for use in listed medicines, and by setting out important requirements relating to the use of those ingredients in such medicines (such requirements may relate, for example, to maximum concentrations of such ingredients in listed medicines, or to the inclusion of warning statements on medicine labels such as ‘Keep out of reach of children’ for relevant ingredients), the safety of Australian consumers will be better protected, and they will be better able to make informed decisions about such medicines.

This is particularly important for listed medicines, given that those medicines are not evaluated for safety and quality by the TGA prior to listing in the Register, and as they are usually available for self-selection by consumers without a requirement to first obtain the advice or prescription of a registered medical doctor, or the advice of a pharmacist.

**Conclusion**

This legislative instrument is compatible with human rights because it promotes the right to health in Article 12 of the ICESCR and does not raise any other human rights issues.